Effectivity of Esomeprazole Compared with Lansoprazole in the Treatment of Pediatric with Gastritis

Fini Kollins; Supriatmo Supriatmo; Rina Saragih; Ilhamd Ilhamd

doi:10.3889/oamjms.2021.7191

Authors

Fini Kollins Department of Pediatric, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Supriatmo Supriatmo Department of Pediatric, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Rina Saragih Department of Pediatric, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0001-6931-1075
Ilhamd Ilhamd Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.7191

Keywords:

Effectivity, Children, Gastritis, Esomeprazole, Lansoprazole

Abstract

BACKGROUND: The administration of proton pump inhibitor (PPI) therapy in pediatric patients has also increased dramatically during the last three decades. Clinical trials comparison of esomeprazole and lansoprazole for pediatric were limited.

AIM: This study focused on comparing the effectivity of Esomeprazole with lansoprazole for healing gastritis symptoms in pediatric patients.

METHODS: A randomized and single blind (assessors) controlled clinical trial was done at H. Adam Malik hospital at Medan. Patients that complied with study’s criteria and signed informed consent were collected information about the symptoms. Confirmation diagnosis of g astritis by gastroscopy, then randomized into lansoprazole treatment group (15 mg if < 30 kg and 30 mg if > 30 kg) or esomeprazole treatment group (0,4–0,8 mg per Kg body weight). Medication for both groups will be given orally for 14 day s, then evaluated for the initial symptoms. p -value of this study was calculated with the χ²test.

RESULTS: Fifty two patients confirmed gastritis were enrolled in this study; 27 patients received lansoprazole and 25 patients received esomeprazole. There was no difference of effectivity between the two groups for vomiting, hematemesis, and nausea. Lansoprazole treatment for 14 days has a significant difference for abdominal pain recovery from esomeprazole treatment. The lansoprazole groups have 92% free of abdominal pain compared to the esomeprazole group for only 66% free of abdominal pain.

CONCLUSION: There was no significant difference between lansoprazole and esomeprazole therapy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Drumm B, Rhoads JM, Stringer DA, Sherman PM, Ellis LE, Durie PR. Peptic ulcer disease in children: Etiology, clinical findings, and clinical course. Pediatrics. 1988;82(3):410-4. PMid:3405676

Blecker U, Mehta DI, Gold BD. Pediatric gastritis and peptic ulcer disease. Indian J Pediatr. 1999;66(5):725-33. https://doi.org/10.1007/BF02726263 PMid:10798134 DOI: https://doi.org/10.1007/BF02726263

Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45(4):421-7. https://doi.org/10.1097/MPG.0b013e31812e0149 PMid:18030207 DOI: https://doi.org/10.1097/MPG.0b013e31812e0149

Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: Mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Pediatr Drugs. 2013;15(2):119-31. https://doi.org/10.1007/s40272-013-0012-x PMid:23512128 DOI: https://doi.org/10.1007/s40272-013-0012-x

Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol. 2003;98(12):2616-20. PMid:14687806 DOI: https://doi.org/10.1111/j.1572-0241.2003.08783.x

Kato S, Nishino Y, Ozawa K, Konno M, Maisawa S, Toyoda S, et al. The prevalence of Helicobacter pylori in Japanese children with gastritis or peptic ulcer disease. J Gastroenterol. 2004;39(8):734-8. https://doi.org/10.1007/s00535-004-1381-2 PMid:15338366 DOI: https://doi.org/10.1007/s00535-004-1381-2

Sierra D, Wood M, Kolli S, Felipez LM. Pediatric gastritis, gastropathy, and peptic ulcer disease. Pediatr Rev. 2018;39(11):542-9. https://doi.org/10.1542/pir.2017-0234 PMid:30385583 DOI: https://doi.org/10.1542/pir.2017-0234

Ertem D, Harmanci H, Pehlivanoğlu E. Helicobacter pylori infection in Turkish preschool and school children: Role of socioeconomic factors and breast feeding. Turk J Pediatr. 2003;45(2):114-22. PMid:12921297

Boukthir S, Aouididi F, Mazigh Mrad S, Fetni I, Bouyahya O, Gharsallah L, et al. Chronic gastritis in children. Tunis Med. 2007;85(9):756-60. PMid:18254306

Koebnick C, Getahun D, Smith N, Porter AH, Der-Sarkissian JK, Jacobsen SJ. Extreme childhood obesity is associated with increased risk for gastroesophageal reflux disease in a large population-based study. Int J Pediatr Obes. 2011;6(2):e257-63. https://doi.org/10.3109/17477166.2010.491118. PMid:20615162 DOI: https://doi.org/10.3109/17477166.2010.491118

Shakhnovich V, Smith PB, Guptill JT, Zhao J, Kearns GL. Obese children require lower doses of pantoprazole than nonobese peers to achieve equal systemic drug exposures. J Pediatr. 2018;193:102-8.e1. https://doi.org/10.1016/j.jpeds.2017.10.011 PMid:29389444 DOI: https://doi.org/10.1016/j.jpeds.2017.10.011

Shakhnovich V, Abdel-Rahman S, Friesen CA, Weigel J, Pearce RE, Gaedigk A, et al. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Pediatr Obes. 2019;14(1):1-4. https://doi.org/10.1111/ijpo.12459 PMid:30257076 DOI: https://doi.org/10.1111/ijpo.12459

Mohn ES, Kern HJ, Saltzman, Mitmesser SH, McKay DL. Evidence of drug-nutrient interacctions with chronic use of commonly prescribed medications: An update. Pharmaceutics. 2018;10(1):36. https://doi.org/10.3390/pharmaceutics10010036 PMid:29558445 DOI: https://doi.org/10.3390/pharmaceutics10010036

Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2005;21(4):455-63. https://doi.org/10.1111/j.1365-2036.2005.02339.x PMid:15709997 DOI: https://doi.org/10.1111/j.1365-2036.2005.02339.x

Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97(3):575-83. https://doi.org/10.1111/j.1572-0241.2002.05532.x PMid:11922549 DOI: https://doi.org/10.1111/j.1572-0241.2002.05532.x

Chey W, Huang B, Jackson RL. Lansoprazole and esomeprazole in symptomatic GERD: A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Investig. 2003;23(2):69-84. https://doi.org/10.2165/00044011-200323020-00001 DOI: https://doi.org/10.2165/00044011-200323020-00001

Faure C, Michaud L, Khan Shaghaghi E, Popon M, Laurence M, Mougenot JF, et al. Lansoprazole in children: Pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther. 2001;15(9):1397-402. https://doi.org/10.1046/j.1365-2036.2001.01076.x PMid:11552911 DOI: https://doi.org/10.1046/j.1365-2036.2001.01076.x

Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2008;46(5):524-33. https://doi.org/10.1097/MPG.0b013e318176b2cb PMid:18493207 DOI: https://doi.org/10.1097/MPG.0b013e318176b2cb